...Pfizer's patent cliff is manageable, with only 13% of revenues exposed to patent expiration in the next three years. Enbrel, in particular, is expected to lose less market than what typically occurs with small molecules....
Navigator
Enter the keyword(s) you would like to search for within this report:
Fitch: New Treasury Rules Sink Pfizer-Allergan Deal – 2016/04/07 – US$ 149.00
Fitch Affirms Pfizer's IDR at 'A+'; Rating Outlook Stable – 2016/04/07 – US$ 149.00
Fitch Rates Pfizer's Notes Offering 'A+' – 2016/06/01 – US$ 149.00
Fitch: Pfizer's Scrapped Split Decision Won't Hurt Ratings – 2016/09/27 – US$ 149.00
Fitch Rates Pfizer's Notes Offering 'A+(exp)'; Outlook Stable – 2016/11/15 – US$ 149.00
Fitch: Innovation, Regulation & Political Risks Key 2017 Themes for Global Pharma and Biotech – 2016/11/30 – US$ 149.00
Pfizer Inc. - Ratings Navigator – 2016/01/07 – US$ 500.00
2017 Outlook: Global Pharma and Biotech – 2016/11/30 – US$ 750.00
Fitch Rates Pfizer's Exchange Notes Offering 'A+'; Outlook Stable – 2015/09/08 – US$ 149.00
Fitch Places Pfizer's L-T Ratings on Negative Watch Following Allergan Merger Announcement – 2015/11/23 – US$ 149.00
Fitch Research—Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.
Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.
Search all our Credit Research from one place.